奧翔藥業(603229.SZ):子公司麒正藥業獲得藥品生產許可證
格隆匯3月28日丨奧翔藥業(603229.SZ)公佈,近日,公司全資子公司麒正藥業收到浙江省藥品監督管理局頒發的《藥品生產許可證》。
本次系麒正藥業首次獲得《藥品生產許可證》,為麒正藥業未來製劑產品獲得上市許可、進行商業化生產提供了資質保障;有利於促進仿製藥製劑及CDMO製劑的發展,實現公司“中間體+特色原料藥+製劑”的一體化升級。麒正藥業尚需取得藥品批准文號及通過GMP認證後方可進行商業化生產,本次獲得《藥品生產許可證》短期內不會對公司業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.